To ensure that the new antimalarial formulation ASAQ (artesunate + amodiaquine) for treatment of uncompliated Plasmodium falciparum malaria became rapidly and widely acessible to patients following its launch, DNDi conducted a policy and market survey in 6 African countries that had already adopted ASAQ as first-line treatment; data from 2 countries were available at the time of writing. It was concluded that more needed to be done to improve availability of the treatment.
Amuasi, J.H.; Karikari, Y.; Boakye, I.; Deley, A.; Blay, S.; Karenzo, J.; Nsabiyumva, L.; Jambai, A.; Baker, S.; Diap, G. Artemisinin combination therapies: policy and market surveys in Burundi and Sierra Leone. Presented at The American Society of Tropical Medicine and Hygiene 58th Annual Meeting, Washington, DC, USA, 18-22 November 2009. (2009)